Research Article
Validation of a Liquid Chromatography-Tandem Mass Spectrometric Assay for Quantitative Analysis of Lenvatinib in Human Plasma
Table 1
Stability of lenvatinib in human plasma and stock solutions.
| Condition | Matrix | Mean nominal conc. | Mean measured conc. | Recovery | CV | ng/mL | ng/mL | % | % |
| −70mLc.d1 month | 3.3 mM HCl/CH3OH | 57800 | 55300 | 95.7 | 2.4 | −2070HHC month | Plasma | 9.6 | 9.2 | 95.8 | 1.6 | −208aHHC month | Plasma | 200.6 | 201.3 | 100.3 | 0.46 | 3 freeze and thaw cycles | Plasma | 11.5 | 10.4 | 90.4 | 1.6 | 3 freeze and thaw cycles | Plasma | 179.8 | 155.6 | 86.5 | 0.79 | Room temperature for 24 hours | Plasma | 11.5 | 11.3 | 98.2 | 2.6 | Room temperature for 24 hours | Plasma | 179.8 | 177.4 | 98.6 | 2.8 | Autosampler | After treatment | 10.1 | 9.3 | 92 | 7.3 | Autosampler | After treatment | 199.3 | 190.6 | 95.6 | 1.8 |
|
|